Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Fineline Cube Feb 11, 2026
Company Deals Digital

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Fineline Cube Feb 11, 2026
Company Deals

Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China

Fineline Cube Feb 10, 2026
Company Deals

Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Fineline Cube Feb 11, 2026
Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Fineline Cube Feb 11, 2026
Company Drug

Jiangsu Hengrui Secures NMPA Approval for Clinical Trials of SHR-2106 in Primary Sjögren’s Syndrome

Fineline Cube Aug 16, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical trial...

Company Medical Device

Lepu Scientech Secures NMPA Approval for MemoSORB Biodegradable Atrial Septal Defect Occluder

Fineline Cube Aug 16, 2024

Lepu Scientech Medical Technology (Shanghai) Co., Ltd. (HKG: 2291) has announced that it has received...

Company Medical Device

Sino Medical Secures Moroccan Approvals for NC Rockstar Catheter and HT Supreme Stent System

Fineline Cube Aug 16, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), a prominent player in China’s medical device sector,...

Company Drug

Vimgreen Pharma Launches Phase II Trial for A2AR Antagonist VG081821AC in Parkinson’s Disease

Fineline Cube Aug 16, 2024

Zhejiang-based Vimgreen Pharma has announced the launch of a Phase II clinical trial for its...

Company Drug

Gilead Secures FDA Accelerated Approval for Livdelzi in Liver Disease Treatment

Fineline Cube Aug 15, 2024

Gilead Sciences Inc. (NASDAQ: GILD) has received accelerated approval from the U.S. FDA for its...

Company Drug

Astellas Pharma Secures UK Approval for First-in-Class Gastric Cancer Therapy Vyloy

Fineline Cube Aug 15, 2024

Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has secured market approval in the...

Company

GSK’s Ma Zheng to Depart as Head of Communication and Government Affairs in China

Fineline Cube Aug 15, 2024

Ma Zheng, the head of communication and government affairs for GSK plc (NYSE: GSK) in...

Company Deals Medical Device

Shanghai Sanyou Medical to Acquire Full Control of SMTP Technology for RMB 415.7 Million

Fineline Cube Aug 15, 2024

Shanghai Sanyou Medical Co., Ltd. (SHA: 688085), based in China, is set to acquire the...

Company Deals Drug

Shandong Buchang Pharmaceuticals Partners with Lancet for BC001 Licensing in Eurasia

Fineline Cube Aug 15, 2024

Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858), based in China, has announced plans to enter...

Company Drug

Biogen and Eisai Secure UAE Approval for Alzheimer’s Therapy Leqembi

Fineline Cube Aug 15, 2024

Biogen Inc. (NASDAQ: BIIB), based in the U.S., and Japan’s Eisai Co., Ltd. have announced...

Policy / Regulatory

Shaanxi Leads New Provincial Alliance for Volume-Based Procurement of Medical Products

Fineline Cube Aug 15, 2024

The Shaanxi Public Resources Trading Center has announced the formation of a provincial alliance for...

Company Drug

CStone to Manufacture Gavreto Locally Following NMPA Approval, Expanding Market Presence

Fineline Cube Aug 15, 2024

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has received approval from the National Medical...

Company Medical Device

China’s Sansure Biotech Launches Approved Kit for Alzheimer’s and Cardiovascular Risk Assessment

Fineline Cube Aug 15, 2024

Sansure Biotech Inc. (SHA: 688289), a China-based leader in molecular diagnostics, has secured marketing approval...

Company Drug

Qilu Pharmaceutical Gains Approval for Generic Dasatinib, Expanding CML Treatment Options in China

Fineline Cube Aug 14, 2024

Qilu Pharmaceutical, based in China, has received marketing approval for its generic version of Bristol-Myers...

Company

Eli Lilly Unveils $700 Million R&D Center in Boston to Boost Genetic Medicine Efforts

Fineline Cube Aug 14, 2024

Eli Lilly & Co. (NYSE: LLY) has inaugurated its new R&D center in Boston’s Seaport...

Company Drug

Ascentage Pharma Secures NMPA Approval for Phase III Trial of Lisaftoclax in MDS

Fineline Cube Aug 14, 2024

Ascentage Pharma (HKG: 6855), based in China, has received approval from the National Medical Products...

Company Drug

Enhertu Gains Conditional Approval in China for Advanced HER2-Positive Gastric Cancer

Fineline Cube Aug 14, 2024

Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate co-developed by AstraZeneca (NASDAQ: AZN, LON: AZN) and...

Company Deals R&D

New Agreement Enhances Myopia Solutions: Hong Kong Polytechnic and Zeiss Collaborate

Fineline Cube Aug 14, 2024

The School of Optometry at Hong Kong Polytechnic University has announced a new cooperation agreement...

Company Medical Device

Lepu Medical’s PeakHeat Vascular Sheath Gains Regulatory Green Light for Market Launch

Fineline Cube Aug 14, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions...

Company Drug Legal / IP

Novartis Intensifies Legal Action Against FDA Over Entresto Generic Approval

Fineline Cube Aug 14, 2024

Novartis Inc. (NYSE: NVS) is intensifying its efforts to thwart the entry of generic competitors...

Posts pagination

1 … 270 271 272 … 622

Recent updates

  • China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million
  • Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial
  • Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder
  • Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device
  • Eisai Biogen’s LEQEMBI Subcutaneous Autoinjector Wins NMPA Priority Review in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.